000 01374 a2200337 4500
005 20250516104822.0
264 0 _c20121231
008 201212s 0 0 eng d
022 _a1520-4804
024 7 _a10.1021/jm300493m
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aHochdörffer, Katrin
245 0 0 _aDevelopment of novel bisphosphonate prodrugs of doxorubicin for targeting bone metastases that are cleaved pH dependently or by cathepsin B: synthesis, cleavage properties, and binding properties to hydroxyapatite as well as bone matrix.
_h[electronic resource]
260 _bJournal of medicinal chemistry
_cSep 2012
300 _a7502-15 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aBone Neoplasms
_xdrug therapy
650 0 4 _aBone and Bones
_xmetabolism
650 0 4 _aCathepsin B
_xmetabolism
650 0 4 _aDiphosphonates
_xmetabolism
650 0 4 _aDoxorubicin
_xmetabolism
650 0 4 _aDurapatite
_xmetabolism
650 0 4 _aHumans
650 0 4 _aHydrogen-Ion Concentration
650 0 4 _aProdrugs
_xmetabolism
700 1 _aAbu Ajaj, Khalid
700 1 _aSchäfer-Obodozie, Cynthia
700 1 _aKratz, Felix
773 0 _tJournal of medicinal chemistry
_gvol. 55
_gno. 17
_gp. 7502-15
856 4 0 _uhttps://doi.org/10.1021/jm300493m
_zAvailable from publisher's website
999 _c22014990
_d22014990